http://www.globalwatchservice.com/pages/TwoColumns.aspx?PageID=439&ProfileID=1010&UseRef=False

Heres a recommendation from Hoods mind you since then ERX has had a bit of dilution, but i would not say no to 7.75p

EIRX THERAPEUTICS PLC
("EiRx" or "the Company")

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in
animal studies


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce the results of
preclinical studies, including preliminary in vivo animal efficacy for its lead
compound ERX3722.

A lead series of molecules (which included ERX3722) was identified from a screen
of kinase inhibitors using EiRx's EnPad(TM)technology. In cell line based in
vitro studies, these molecules demonstrated selective killing of breast cancer
cells over non-cancerous breast cells. Following a patent application in August
2005, ADME (Administration, Distribution, Metabolism, Excretion) studies
identified ERX3722 (Mw 331) as having favourable drug like properties in terms
of metabolic stability, serum binding, P-gp inhibition, Caco-2 efflux, and
Cyp450 inhibition. The compound is also very well tolerated with little or no
toxic effects on normal tissues detected, in maximum tolerated dose studies.

For the in vivo efficacy studies, mice bearing a subcutaneous human breast
cancer xenograft were treated with the compound at several different dosing
regimens. All treatment groups responded with a reduction in tumour volume,
relative to the untreated control, with the higher doses achieving a very
significant 50% reduction in tumour volume.

In addition to this significant efficacy, it was observed that during the
treatment regime, the mice did not show any toxic or side effects, such as
weight loss, associated with compound administration. This suggests that the
compound is highly selective for the tumour, unlike the more traditional cancers
therapies, where effectiveness can be limited due to associated toxicities.

"A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant" said
Professor Tom Cotter, founder and CSO of EiRx. "We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

Commenting on the results, Dr. Finbarr Murphy, Managing Director of operating
subsidiary EiRx Therapeutics Ltd, said: "The efficacy and selectivity of the
molecule is very encouraging, and supports our approach of targeted apoptosis
therapy in the treatment of cancer to limit toxicity and side effects associated
with standard chemotherapy.

Across the seven major markets, 443,000 women were estimated to have developed
breast cancer in 2004, with an estimated 112,000 dying from the disease. The
incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

I hope you listened the MGI webcast last week by the way, ZYC300 is talked about

there also a slideshow and ZYC300 it all over it..

http://media.corporate-ir.net/media_files/Phoenix/client//73/73842/Slides/1491262/Decks/c3227a87-239b-489c-80c6-304224e5aa92/slide004.jpg

Adjusted To GAAP Reconciling Items:
1.Amortization of product intangibles
2.Stock based compensation expense
3.License and milestone payments
4.Restructuring expenses

they are now moving into validated clinic for zyc300..

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MOGN&item_id=1491262

suggest you listen to it, it looks like we could get further news this week, phase i/iib is done basically and now moving on

started to move up.. up 5%, large trades starting to show up, due to problem with monitor price rise not showing on monam but is on other websites

Kat
are those [2m x2 &5m x 1] buys or sells? judging by your last do you think they are buys.
Alex

I believe they are shorts starting to close actually. I believe there are going to be a lot more this afternoon.. I am expecting a big update tonight on the MGI webcast as last week they started talking about our product and that more news was coming very shortly. in fact todays webcast was brought forward from tomorrow, the webcast is at 4.30, so if we do get the news I am expecting.. then an rns should be issued first thing, remember zyc300 last week they said it is now in validated clinic, which means the results are out ahead of 1st April 2007.. and by all accounts its good news as well